The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Merck; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Dale L. Nepert
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Kenton Wride
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Daleen Thomas
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Andrea Loehr
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Andrew Simmons
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Consulting or Advisory Role - Redwood Bioscience
 
Simon Chowdhury
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Clovis Oncology; Janssen; Pfizer; Sanofi
Research Funding - Johnson & Johnson; Sanofi